7 unchanged sentences
Incorporated by Reference
+Added: Distribution Agreement, dated January 14, 2022, by and among Plus Therapeutics, Inc.
+Added: and Canaccord Genuity LLC
+Added: Composite Certificate of Incorporation
+Added: Certificate of Amendment to Amended and Restated Certificate
+Added: Certificate of Amendment to Amended and Restated Certificate
+Added: Certificate of Amendment to Amended and Restated Certificate
+Added: Certificate of Amendment to Amended and Restated Certificate
Amended and Restated Bylaws of Plus Therapeutics, Inc.
−Removed: Certification of Elimination of Series A Preferred Stock.
−Removed: LaFrance Employment Agreement.
+Added: Medidata Services Agreement and Statement of Work
+Added: Distribution Agreement, dated January 14, 2022, by and among Plus Therapeutics, Inc.
+Added: and Canaccord Genuity LLC.
Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rule 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
9 unchanged sentences
Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)
+Added: + Portions of this exhibit have been excluded in compliance with Item 601 of Regulation S-K.
In accordance with Item 601(b)(32)(ii) of Regulation S‑K and SEC Release No.
2 unchanged sentences
PLUS THERAPEUTICS, INC.
−Removed: October 21, 2021
+Added: April 21, 2022
President & Chief Executive Officer (Duly Authorized Officer and Principal Executive Officer)
/s/ Andrew Sims
−Removed: October 21, 2021
+Added: April 21, 2022
Chief Financial Officer (Duly Authorized Officer and Principal Financial Officer and Principal Accounting Officer)
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.